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antibodiesAbstract Background: Henoch–Scho¨nlein purpura (HSP) is an uncommon vasculitis in adults.
Gastrointestinal involvement is part of the classical tetrad and can present as bleeding. Helicobacter
pylori infection in the setting of HSP has been reported a few times in the literature and may be
involved in the pathogenesis of this disease as a triggering agent.
Case report: A 48-year-old man presented to the emergency department with 9 days of acute
symmetric additive polyarthritis, 2 days of palpable purpura involving lower limbs, recent-onset
intense mesogastric pain and hematochezia. H. pylori was detected in gastric tissue and triple ther-
apy (clarithromycin, amoxicillin and omeprazole) was started. Gastrointestinal bleeding and other
symptoms stopped 24 h after steroid initiation and he was later discharged on prednisone (1 mg/kg)
and azathioprine (100 mg/day). Shortly after discharge he was readmitted with hematochezia and
clarithromycin-resistant H. pylori infection was suspected. Bleeding stopped following reinstitution
of corticosteroids and a second-line scheme (levofloxacin, amoxicillin and omeprazole) was intro-
duced. Corticosteroids were gradually tapered and he remained on azathioprine. Nine months later
he was doing fine. The pertinent literature is briefly discussed, highlighting the previous cases of
concurrent diagnosis in adult patients.e Nuevo
122 G. Delgado-Garcı´a et al.Conclusion: To the best of our knowledge, this is the first report describing resistance to
clarithromycin-containing triple therapy in a H. pylori-infected adult patient with HSP. Gastroin-
testinal bleeding remains one of the most feared manifestations of HSP. These patients may benefit
from H. pylori screening, as this might positively affect their prognosis. Further studies in adults are
nevertheless needed to clarify this association and its therapeutic impact.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Henoch–Scho¨nlein purpura (HSP) is an uncommon vasculitis
in adults, with an annual estimated incidence of 8–18 cases
per million [1]. Gastrointestinal involvement is part of the clas-
sical tetrad and occurs in one in ten adult patients at disease
onset and in more than half of the cases when the disease is
fully established [2,3]. Hemorrhage is one of the most severe
manifestations of gastrointestinal involvement [4]. Helicobac-
ter pylori infection in the setting of HSP has been reported a
few times in the literature, but its role in the course of this dis-
ease remains controversial [5]. Here, we describe the case of a
male patient presenting with gastrointestinal bleeding, as a
manifestation of HSP, in whom H. pylori infection was also
diagnosed, and then we discuss the pertinent literature.
2. Case report
A 48-year-old man with a medical history notable for newly
diagnosed type 2 diabetes presented to the emergency depart-
ment with 9 days of acute symmetric additive polyarthritis,
2 days of palpable purpura involving lower limbs and recent-
onset intense mesogastric pain. On further questioning, he
revealed that he recently suffered from constipation that
required manual disimpaction. Soon after that, he developed
hematochezia, which was self-limited and without hemody-
namic compromise. He was febrile and had a heart rate of
117 bpm. His abdomen was soft with no peritoneal irritation
signs. Initial laboratory workup showed no significant alter-
ations in complete blood count. His serum creatinine was
0.6 mg/dL and C-reactive protein 98.5 mg/dL (upper normal
limit: 6 mg/dL). No abnormalities were found on urinalysis.
Fecal immunochemical test was positive for occult blood.
ELISA for human immunodeficiency virus, hepatitis B surface
antigen and anti-hepatitis C virus were all negative. Hud-
dleson’s reaction was also negative. He was positive for perin-
uclear anti-neutrophil cytoplasmic antibodies (pANCA) with a
titer of 1:640. Antinuclear, anti-MPO and anti-PR3 antibodies,
as well as rheumatoid factor, were all negative. No lesions were
found in the contrast-enhanced abdominal computerized
tomography scan. Under the suspicion of vasculitic process,
a skin biopsy was performed on the same admission day. He
remained under observation until his second inpatient day
when he had hematochezia and was thus started on prednisone
(1 mg/kg).
Ringed esophagus, esophageal mucosal erythema, gastric
subepithelial hemorrhage, duodenal erythema with an ulcer
<1 cm were noted on upper endoscopy. Descending colonic
and rectal mucosal erythema, and rectal edema and subepi-
thelial hemorrhage were found on rectosigmoidoscopy.
Histopathology of biopsy specimens revealed chronicesophagitis compatible with reflux disease, active chronic gas-
tritis, acute ulcerated duodenitis, focal active colitis, and
edema and congestion of the rectal lamina propria.
Immunofluorescence was not performed. H. pylori was
detected in gastric tissue and he was therefore started on triple
therapy (clarithromycin, amoxicillin and omeprazole).
Leukocytoclastic vasculitis was confirmed by skin
histopathology and immunofluorescence demonstrated granu-
lar vascular deposits of IgA (+2), confirming the presumptive
diagnosis of HSP. Bleeding and other symptoms stopped 24 h
after steroid initiation and he was later discharged on pred-
nisone and azathioprine (100 mg daily).
He skipped some doses of his medications and, shortly after
discharge, was readmitted with hematochezia. Bleeding
stopped following reinstitution of corticosteroid therapy.
One month after finishing triple therapy, urea breath test
(UBT) was performed and interpreted as positive, so we
started him on a second-line scheme (levofloxacin, amoxicillin
and omeprazole). He completed his treatment regimen and,
four weeks later, UBT was repeated and tested negative.
Corticosteroid therapy was gradually tapered and he remained
on azathioprine. Nine months later, on the follow-up, he was
doing fine and reported no symptoms.
3. Discussion
Gastrointestinal bleeding is considered a severe gastrointesti-
nal manifestation of HSP and, in the largest unselected series
to date, occurred in about 23 percent of patients, either as
occult (10.3%) or overt hemorrhage (12.9%) [3,4]. However,
it is worth noting that children were included in the previous
figures and also that gastrointestinal involvement was more
frequent in children than adults (67.3% vs 57.4%; p< 0.05)
[3]. Gastrointestinal symptoms may precede the skin involve-
ment and have been ascribed to immune complex deposition
in vessel walls which lead to edema and hemorrhage [2].
pANCA with negative ELISA-ANCA has been previously
detected in HSP patients with gastrointestinal symptoms and
this may indicate that the ANCA target antigens may be differ-
ent in HSP. These patients had higher disease activity [6]. Gas-
tric and duodenal endoscopic appearance of HSP was first
described in a 14 year-old girl by Akdamar et al. in 1973 [7].
Colonoscopic findings have been reported more rarely and
were first described in two adult patients more than a decade
later by Di Febo et al. [8,9]. The main findings include redness,
petechiae, erosion, nodular changes, ulceration and strictures.
These lesions are predominantly distributed in the second
part of the duodenum, terminal ileum and rectosigmoid
colon [10,11]. Concurrent involvement of upper and lower
gastrointestinal tracts may not be uncommon as long as both
upper endoscopy and colonoscopy are performed [11].
Table 1 Adult-onset HSP patients with concurrent H. pylori infection.
Case Author Country Year Sex Age GIB Cr (mg/dL) Proteinuria (g/d) ANA ANCA H. pylori PPI Antibiotics Relapse
1 Reinauer et al. Germany 1995 F 21 Positive 1.2 1.2 Negative Negative UBT / Bx Positive Amp No§
2 Machet et al. France 1997 M 65 Positive 0.8 3 Negative NR Bx Positive Amp + CLR+Dap No
3 Cecchi et al. Italy 1998 M 62 FOBT Normal 0.5 Negative Negative RUT Positive Amox + CLR No
4 Nova´k et al.* Hungary 2003 M 38 NR NR NR NR UBT / Bx NR NR NR
5 M 53 NR NR NR NR UBT / Bx NR NR NR
6 M 54 NR NR NR NR Bx NR NR NR
7 Kellerman USA 2006 M 65 Negative 3.9 6.2 Negative 1:80 SAT Positive Amp + CLR y
8 Grivceva-Panovska et al. Macedonia 2008 M 29 Negative Normal Negative Negative NR IgG serology Positive CLR+MTZ No
9 Hoshino Japan 2009 M 33 FOBT 0.89 Negative Negative Negative RUT Positive Amox + CLR No§
10 Hamzaoui et al. Tunisia 2011 F 62 Positive Normal 3.3 NR NR Bx NR NR No
11 M 20 Negative Normal Negative NR NR Bx Positive NR No
12 Ulas et al. Turkey 2012 M 49 FOBT Normal 0.45 Negative NR RUT+ Bx Positive Amox + CLR No
13 Berriche et al. Tunisia 2014 M 67 Negative 1.8 0.6 Negative Negative Bx Positive Amox + CLR No
Patients in remission were eliminated. GIB: gastrointestinal bleeding; Cr: serum creatinine; ANA: antinuclear antibodies; ANCA: antineutrophil cytoplasmic antibodies; H. pylori: Helicobacter
pylori infection; PPI: proton-pump inhibitor; FOBT: positive fecal occult blood test; NR: not reported; UBT: urea breath test; Bx: biopsy; RUT: rapid urease test; SAT: stool antigen test; Amp:
ampicillin; CLR: clarithromycin; Dap: dapsone; Amox: amoxicillin; MTZ: metronidazole.
* One of Nova´k’s patients had GIB, but they did not specify which one.
 Urine protein:creatinine ratio.
y Died during this hospital stay.
§ Reinfection.
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124 G. Delgado-Garcı´a et al.Leukocytoclastic vasculitis could be demonstrated in gastroin-
testinal biopsy samples, especially in severe lesions.
Histopathology is also useful for the differential diagnosis
[10,11]. Based on previous studies and pediatric data,
Audemard-Verger et al. recently proposed an algorithm for
the management of adult patients with gastrointestinal
involvement. For severe manifestations, surgical evaluation
and prednisone (1 mg/kg daily) are recommended. Methyl-
prednisolone pulse therapy and/or cyclophosphamide can also
be considered [13]. In this series, prognosis was not subana-
lyzed according to gastrointestinal involvement. Renal insuffi-
ciency, nephrotic and nephritic syndromes during the course of
HSP is more commonly observed in adults than in children [3,
personal communication]. In a French retrospective, multicen-
ter cohort study, which included 250 adult patients with
biopsy-proven nephritis, gastrointestinal involvement was not
a risk factor for nephritis [12], personal communication.
Relapses are not unexpected in adult patients [13].
Bacterial pathogens have been suspected to trigger HSP [5].
H. pylori has been alike implicated as a causative or triggering
agent of several extradigestive diseases [14]. In the setting of
HSP, H. pylori infection has been reported a few times in the
literature (Table 1) [15–23], but this association may be under-
estimated because it is not deliberately sought [17,21]. Further-
more, H. pylori role in the natural history of HSP remains a
matter of debate [5]. Directly or via immune or inflammatory
processes, H. pylori might be involved in HSP pathogenesis
[21]. Shin et al. have speculated that increased serum IgA,
decreased C3 levels, and increased cryoglobulins by H. pylori
infection might favor the formation of immune complexes
and trigger the development of HSP [24]. Xiong et al. con-
ducted a meta-analysis to assess the association between
H. pylori infection and HSP in Chinese children. They found
that children with HSP had a higher incidence of infection
than control subjects (49.27% vs 23.39%, respectively). The
pooled odds ratio (OR) for H. pylori infection among children
with HSP, compared with control subjects, was 3.80 (95% CI:
2.54–5.68). Cumulative meta-analysis was also performed and
confirmed this association with a narrower confidence interval
(OR = 3.35, 95% CI: 2.95–3.81). Moreover, the pooled OR
for H. pylori infection among HSP patients with predominant
gastrointestinal symptoms was 4.62 (95% CI: 2.66–8.01,
p< 0.001). H. pylori eradication decreased the recurrence rate
of HSP in infected children (RR= 0.38, 95% CI: 0.25–0.58,
p< 0.001) [25]. On the other hand, Cai et al. found no signif-
icant difference in recurrence rate with the use of triple therapy
in infected children (14% vs 24%). The incidence of nephritis
was, nevertheless, lower in those children who were treated
with triple therapy (5% vs 33%, p< 0.05) [14,26].
Results of the previous studies should be interpreted in light
of at least two limitations. First, the age of the population
studied, since prognosis may vary according to the age of onset
[3]. Second, the diversity in H. pylori isolates from different
populations, as these may differ between Chinese and non-
Chinese populations [25]. In relation to the above, Nova´k
et al. studied 11 Hungarian adult patients with HSP and found
that anti-H. pylori IgG concentration was higher in those with
acute disease (n= 5) than in those in remission (n= 6)
(86 ± 32 vs 32.5 ± 23.2 U/ml, p< 0.05). They also had a
higher concentration than control subjects (n= 20) (86 ± 32
vs 25.5 ± 28.5 U/ml, p< 0.05). In addition, total IgA concen-
tration was higher in patients with acute disease compared tothose in the control group (5.5 ± 1.1 vs 2.43 ± 1.2 g/L,
p< 0.05) [18].
Because of the rarity of this vasculitis in a country where
H. pylori infection is fairly prevalent among adults [27], this
pathogen is probably not the sole factor involved in HSP
pathogenesis. Moreover, a patient who has been treated for
HSP associated with H. pylori infection can be reinfected
without showing symptoms of HSP [21]. According to the
Maastricht IV/Florence Consensus Report, the evidence avail-
able shows no clear causal association or therapeutic link
between H. pylori and other extradigestive disorders [28], such
as HSP. However, the Kyoto global consensus report strongly
recommends that infected patients should be offered eradica-
tion therapy [29]. Because of its high degree of accuracy and
non-invasiveness [28], UBT may be thus useful as a screening
tool in HSP patients, especially in those corticoresistant, corti-
codependent or with predominant gastrointestinal symptoms.
It is also important to confirm H. pylori eradication at the
end of the treatment. To the best of our knowledge, this is
the first report describing resistance to clarithromycin-
containing triple therapy in a H. pylori-infected adult patient
with HSP. This is of special interest as Garza-Gonza´lez et al.
previously reported that our city is part of a region with low
clarithromycin resistance (8.1%) [30]. Therefore, even in these
areas, clarithromycin resistance should be considered in any
H. pylori-infected patient with HSP who continue to deterio-
rate clinically despite steroid and triple therapy.
In conclusion, gastrointestinal bleeding is one of the most
severe gastrointestinal manifestations of HSP. These patients
may benefit from H. pylori screening, as this might positively
affect their prognosis. Further studies in adults are neverthe-
less needed to clarify this association and its therapeutic
impact.
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